In this multicenter longitudinal cohort study, we explored the clinical utility of plasma p-tau217 for detecting AD in individuals with CBS and found plasma p-tau217 was elevated in patients with CBS with positive amyloid or tau PET results and showed excellent diagnostic performance for identifying PET positivity in this cohort. The gene discussed is MAPT; the disease is Alzheimer disease.